Enhanced in vivo antitumor efficacy through the nanodiamond mediated co-delivery of drugs

Mao, 2022, Integrative oncology: addressing the global challenges of cancer prevention and treatment, CA Cancer J. Clin., 72, 144, 10.3322/caac.21706 Corrie, 2008, Cytotoxic chemotherapy: clinical aspects, Medicine, 36, 24, 10.1016/j.mpmed.2007.10.012 Tacar, 2012, Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems, J. Pharm. Pharmacol., 65, 157, 10.1111/j.2042-7158.2012.01567.x Cummings, 1993, DNA topoisomerase-1 and topoisomerase-2 as targets for rational design of new anticancer drugs, Ann. Oncol., 4, 533, 10.1093/oxfordjournals.annonc.a058584 Evison, 2016, Mitoxantrone, more than just another topoisomerase II Poison, Med. Res. Rev., 36, 248, 10.1002/med.21364 Dantchev, 1984, Comparative microscopic study of cardiotoxicity and skin toxicity of anthracycline analogs, Biomed. Pharmacother., 38, 322 Bontenbal, 1992, Weekly low-dose mitoxantrone plus doxorubicin as second-line chemotherapy for advanced breast cancer, Breast Cancer Res. Treat., 21, 133, 10.1007/BF01836959 Stewart, 1987, Combined mitoxantrone plus doxorubicin in the treatment of breast cancer, Am. J. Clin. Oncol., 10, 335, 10.1097/00000421-198708000-00016 Kurbacher, 1996, Heterogeneity of in vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubicin evaluated by a microplate ATP bioluminescence assay, Breast Cancer Res. Treat., 41, 161, 10.1007/BF01807161 Damiani, 2016, Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone, Arch. Toxicol., 90, 2063, 10.1007/s00204-016-1759-y Barenholz, 2012, Doxil — the first FDA-approved nano-drug: lessons learned, J. Contr. Release, 160, 117, 10.1016/j.jconrel.2012.03.020 Yuan, 2021, Conjugation with nanodiamonds via hydrazone bond fundamentally alters intracellular distribution and activity of doxorubicin, Int. J. Pharm. (Amst.), 606 Gao, 2019, Nanodiamond‐based theranostic platform for drug delivery and bioimaging, Small, 15, 10.1002/smll.201902238 Garifo, 2021, Nanodiamonds as nanomaterial for biomedical field, Front. Mater. Sci., 15, 334, 10.1007/s11706-021-0567-3 Xu, 2021, Synergy of nanodiamond–doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells, J. Nanobiotechnol., 19, 268, 10.1186/s12951-021-01017-w Turcheniuk, 2017, Biomedical applications of nanodiamond, Nanotechnology, 28, 10.1088/1361-6528/aa6ae4 Whitlow, 2017, Multifunctional nanodiamonds in regenerative medicine: recent advances and future directions, J. Contr. Release, 261, 62, 10.1016/j.jconrel.2017.05.033 Estrella, 2013, Acidity generated by the tumor microenvironment drives local invasion, Cancer Res., 73, 1524, 10.1158/0008-5472.CAN-12-2796 Anderson, 2020, The tumor microenvironment, Curr. Biol., 30, R921, 10.1016/j.cub.2020.06.081 Li, 2016, Smart pH-responsive and high doxorubicin loading nanodiamond for in vivo selective targeting, imaging, and enhancement of anticancer therapy, J. Mater. Chem. B, 4, 5046, 10.1039/C6TB00266H Wu, 2023, A nanodiamond chemotherapeutic folate receptor-targeting prodrug with triggerable drug release, Int. J. Pharm. (Amst.), 630 Wang, 2018, Stimuli-responsive nanodiamond-based biosensor for enhanced metastatic tumor site detection, SLAS Technol, 23, 44, 10.1177/2472630317735497 Deng, 2017, Nanoparticle interactions with co-existing contaminants: joint toxicity, bioaccumulation and risk, Nanotoxicology, 11, 1, 10.1080/17435390.2017.1343404 Miller, 2017, Inhaled nanoparticles accumulate at sites of vascular disease, ACS Nano, 11, 4542, 10.1021/acsnano.6b08551 Miller, 2017, Correction to“inhaled nanoparticles accumulate at sites of vascular disease”, ACS Nano, 11, 10623, 10.1021/acsnano.7b06327 Wang, 2021, Safety evaluation of nanodiamond-doxorubicin complexes in a Naïve Beagle canine model using hematologic, histological, and urine analysis, Nano Res., 1 Toh, 2014, Nanodiamond-mitoxantrone complexes enhance drug retention in chemoresistant breast cancer cells, Mol. Pharm., 11, 2683, 10.1021/mp5001108 Li, 2019, Ultrasound-enhanced delivery of doxorubicin-loaded nanodiamonds from pullulan-all-trans-retinal nanoparticles for effective cancer therapy, ACS Appl. Mater. Interfaces, 11, 20341, 10.1021/acsami.9b03559 Bukowski, 2020, Mechanisms of multidrug resistance in cancer chemotherapy, Int. J. Mol. Sci., 21, 3233, 10.3390/ijms21093233 Wang, 2022, Recent advances in anti-multidrug resistance for nano-drug delivery system, Drug Deliv., 29, 1684, 10.1080/10717544.2022.2079771 Zhu, 2017, Nanodiamond mediated co-delivery of doxorubicin and malaridine to maximize synergistic anti-tumor effects on multi-drug resistant MCF-7/ADR cells, J. Mater. Chem. B, 5, 3531, 10.1039/C7TB00449D Li, 2018, Ultrasound-enhanced delivery of doxorubicin/all-trans retinoic acid-loaded nanodiamonds into tumors, Nanomedicine, 13, 981, 10.2217/nnm-2017-0375 Chou, 2010, Drug combination studies and their synergy quantification using the Chou-Talalay method, Cancer Res., 70, 440, 10.1158/0008-5472.CAN-09-1947 Du, 2020, A tumor-targeted, intracellular activatable and theranostic nanodiamond drug platform for strongly enhanced in vivo antitumor therapy, J. Mater. Chem. B, 8, 1660, 10.1039/C9TB02259G Ridha, 2021, A promising dual-drug targeted delivery system in cancer therapy: nanocomplexes of folate-apoferritin-conjugated cationic solid lipid nanoparticles, Pharmaceut. Dev. Technol., 26, 673, 10.1080/10837450.2021.1920037 Xiao, 2011, The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles, Biomaterials, 32, 3435, 10.1016/j.biomaterials.2011.01.021 Cagel, 2017, Doxorubicin: nanotechnological overviews from bench to bedside, Drug Discov. Today, 22, 270, 10.1016/j.drudis.2016.11.005 Ashton, 2015, Drug combination studies and their synergy quantification using the Chou-Talalay method, Cancer Res., 75, 2400, 10.1158/0008-5472.CAN-14-3763 Shi, 2015, Co-delivery of docetaxel and chloroquine via PEO–PPO–PCL/TPGS micelles for overcoming multidrug resistance, Int. J. Pharm. (Amst.), 495, 932, 10.1016/j.ijpharm.2015.10.009 Vandergraaf, 1994, Effects of amiodarone, cyclosporine-a, and psc-833 on the cytotoxicity of mitoxantrone, doxorubicin, and vivcristine in non-p-glycoprotein human small-cell lung -cancer cell lines, Cancer Res., 54, 5368 Deniaud, 2008, Endoplasmic reticulum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis, Oncogene, 27, 285, 10.1038/sj.onc.1210638 Haeberlein, 2004, Mitochondrial function in apoptotic neuronal cell death, Neurochem. Res., 29, 521, 10.1023/B:NERE.0000014823.74782.b7 Dong, 2015, Folate-conjugated nanodiamond for tumor-targeted drug delivery, RSC Adv., 5, 82711, 10.1039/C5RA12383F Wang, 2013, PEGylated nanodiamond for chemotherapeutic drug delivery, Diam. Relat. Mater., 36, 26, 10.1016/j.diamond.2013.04.002 Rashid, 2001, Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D-3 and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A, Oncogene, 20, 1860, 10.1038/sj.onc.1204269 Guicciardi, 2004, Lysosomes in cell death, Oncogene, 23, 2881, 10.1038/sj.onc.1207512 Maeda, 2010, Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects, Bioconjugate Chem., 21, 797, 10.1021/bc100070g Maeda, 2013, The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo, Adv. Drug Deliv. Rev., 65, 71, 10.1016/j.addr.2012.10.002 Nichols, 2014, EPR: evidence and fallacy, J. Contr. Release, 190, 451, 10.1016/j.jconrel.2014.03.057 Chen, 2015, Theranostic applications of carbon nanomaterials in cancer: focus on imaging and cargo delivery, J. Contr. Release, 210, 230, 10.1016/j.jconrel.2015.04.021 Guissi, 2017, Mitoxantrone- and folate-TPGS2k conjugate hybrid micellar aggregates to circumvent toxicity and enhance efficiency for breast cancer therapy, Mol. Pharm., 14, 1082, 10.1021/acs.molpharmaceut.6b01009 Wei, 2019, OFF-ON nanodiamond drug platform for targeted cancer imaging and therapy, J. Mater. Chem. B, 7, 3390, 10.1039/C9TB00447E